License and supply agreement with Genuine Health
RNS & Investor News
Human study shows formulation with LPLDL® reduces high blood pressure
08 January 2020
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), in partnership with Nutrilinea Srl. ("Nutrilinea") has completed a successful human study for a new food supplement formulation containing LPLDL® and has shown the product can reduce high blood pressure (hypertension).
The study was part of an agreement (RNS: 20 May 2019) with Nutrilinea to fund the development, manufacture, and carrying out of human studies for a new blood pressure product in return for 12 months exclusivity from the date the data was made available from the human study (18 December 2019) for the European market. ProBiotix has exclusivity for the UK and all other markets outside Europe.
The three month study of 40 patients was carried out by the Center of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and showed statistically significant reductions in both systolic, diastolic blood pressure levels, and cholesterol levels. The results of this study are consistent with ProBiotix's initial study conducted at the University of Reading which showed a statistically significant reduction in both blood pressure and cholesterol in volunteers taking LPLDL® (Costabile et al., 2017).
The European Cardiovascular Society reported in 2016 that the combination of lowering LDL cholesterol and systolic blood pressure has the potential to "dramatically reduce" a person's lifetime risk of cardiovascular disease. Hypertension is a global healthcare issue and is one of the strongest risk factors for almost all cardiovascular diseases. The fact that it does not have obvious symptoms has led doctors to call hypertension a 'silent killer'. Studies conducted in Europe and in the United States suggest that, under new hypertension guidelines, a large percentage of the adult population may be considered hypertensive: some 14 million people in the UK and over 100 million in the US.
Steve Prescott, Chief Executive Officer of ProBiotix, commented: "We are very pleased to have partnered with Nutrilinea who covered the cost of the product development, manufacturing, and the human study. Because hypertension effects millions of people globally and is a serious risk factor for cardiovascular disease, we are excited to offer a natural product that has been clinically proven to lower hypertension. Adding this new formulation to our portfolio of existing products that target cholesterol reduction, CholBiome® and CholBiome® x3, allows ProBiotix to offer a best in class cardiovascular health solutions to consumers."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
|OptiBiotix Health Plc
Stephen O’Hara, Chief Executive
Contact via Walbrook below
|Cairn Financial Advisers LLP (NOMAD)||Tel: 020 7213 0880|
|Liam Murray / Jo Turner / Ludovico Lazzaretti|
|finnCap (Broker)||Tel: 020 7220 0500|
|Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
|goetzpartners securities Limited||Tel: 0203 859 7725|
|Walbrook PR Ltd
|Mob: 07876 741 001|
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company’s current areas of focus include obesity, cardiovascular health, and diabetes.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020